CN Patent

CN116478165A — 一种化合物的晶型、其制备和用途

Assigned to Beone Pharmaceutical Suzhou Co Ltd · Expires 2023-07-25 · 3y expired

What this patent protects

本发明涉及用于抑制Btk的(S)‑7‑(1‑丙烯酰基哌啶‑4‑基)‑2‑(4‑苯氧基苯基)‑4,5,6,7‑四氢吡唑并[1,5‑a]嘧啶‑3‑甲酰胺的晶型、其制备方法和药物组合物，以及上述晶型在治疗疾病中的用途或在制备用于治疗疾病的药物中的用途。

USPTO Abstract

本发明涉及用于抑制Btk的(S)‑7‑(1‑丙烯酰基哌啶‑4‑基)‑2‑(4‑苯氧基苯基)‑4,5,6,7‑四氢吡唑并[1,5‑a]嘧啶‑3‑甲酰胺的晶型、其制备方法和药物组合物，以及上述晶型在治疗疾病中的用途或在制备用于治疗疾病的药物中的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN116478165A
Jurisdiction
CN
Classification
—
Expires
2023-07-25
Drug substance claim
No
Drug product claim
No
Assignee
Beone Pharmaceutical Suzhou Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.